AccessibilityHelpAbout Us
Okyo Pharma logo

Okyo Pharma(NASDAQ) OKYO

Market Cap$71.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)-88%
5 YearN/A
1 Year-34%
1 Month-10%
$1.35
+1.89%
+0.03Today
After hours$1.35+$0.00 (+0.00%)
Okyo Pharma last closing stock price
MetricPriceDate
Last closeUSD 1.362026-09-18
Okyo Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.86%USD 1.402026-09-11
1 month-9.93%USD 1.512026-08-19
3 month-14.47%USD 1.592026-06-18
Year to date-34.3%USD 2.072025-12-31
1 year-34.3%USD 2.072025-09-18
3 year-29.9%USD 1.942023-09-19
Since inception-87.94%USD 11.282010-05-05

Okyo Pharma Financials at a Glance

Market Cap

$71.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$13.66M

EPS (TTM)

-$0.19

P/E Ratio

-7.14

Dividend

$0.00

Beta (Volatility)

0.76 (Low)

Price

$1.35

Volume

22,107

Open

$1.32

Previous Close

$1.36

Daily Range

$1.32 - $1.44

52-Week Range

$1.28 - $3.20

Estimated Earnings Date

Aug 10, 2026

OKYO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Okyo Pharma

OKYO Pharma Limited is a biopharmaceutical firm focused on developing innovative treatments for inflammatory eye conditions and ocular discomfort. The company is advancing its primary therapeutic candidate, OK-101, for dry eye disease, alongside OK-201, aimed at treating neuropathic ocular pain. Established in 2007 and headquartered in London, UK, OKYO Pharma operates at the preclinical stage.

Products and Services
  • OK-101 for dry eye disease
  • OK-201 for neuropathic ocular pain
  • Research and development in inflammatory eye conditions
Growth Outlook
  • Strong focus on unmet medical needs in ocular health
  • Potential market expansion with innovative therapies
  • Increased investment in research and development initiatives
Financial Highlights
  • Recent quarterly net income of -$6.36 million
  • Cash and short-term investments of $20.59 million
  • Operating expenses of $6.41 million in the latest quarter
OKYO Pharma Limited is positioned in the biotechnology sector, specifically targeting the healthcare needs of patients suffering from eye-related conditions. The company's innovative approach to treatment development, particularly with its lead candidates, reflects a commitment to addressing significant gaps in current therapeutic options. The financial data indicates a robust cash position, which may support ongoing research and development efforts. Despite recent losses, the focus on expanding product offerings and addressing unmet medical needs presents a compelling narrative for potential growth. Investors may find interest in the company's strategic direction and its potential impact on the ocular health market.
AI Generated • Sep 19, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Robert J. Dempsey, MBA

Website

www.okyopharma.com

Headquarters

London, GL W1S 4JE, GB

OKYO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-200.67%

Return on Capital

-68.91%

Return on Assets

-42.67%

Earnings Yield

-14.01%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$71.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

52.48M

Volume

22.11K

Avg. Volume

105.62K

Financials (TTM)

Gross Profit

-$3.11K

Operating Income

-$16.39M

EBITDA

-$15.62M

Operating Cash Flow

-$7.75M

Capital Expenditure

-$7.29K

Free Cash Flow

-$7.76M

Cash & ST Invst.

$20.59M

Total Debt

$0.00

Okyo Pharma Performance Analysis

Okyo Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 0N/A
20242024-03-31USD 0N/A
20252025-03-31USD 0N/A
20262026-03-31USD 0N/A
Okyo Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-09-30N/A
Q42025-03-31N/A
Q22025-09-30N/A
Q42026-03-31N/A
Okyo Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD -0.6010741.8%
20242024-03-31USD -0.57-3.8%
20252025-03-31USD -0.12-79.2%
20262026-03-31USD -0.24101.0%
Okyo Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-09-30-39800.0%
Q42025-03-3149.6%
Q22025-09-30-71.9%
Q42026-03-31-146.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$935.00

+72.3%

Gross Margin

0.00%

N/A

Market Cap

$71.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$14.27M

N/A

Employees

5

N/A

Net Income

-$6.36M

-78216.9%

EBITDA

-$6.41M

-91279.0%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$20.59M

+2390.7%

Total Debt

$0.00

N/A

Accounts Receivable

$170.67K

-70.6%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-42.67%

N/A

Return on Invested Capital

-74.59%

N/A

Free Cash Flow

-$4.41M

-63.6%

Operating Cash Flow

-$4.41M

-63.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PLRXPliant Therapeutics, Inc.
$1.11-1.77%
TLSATiziana Life Sciences Ltd
$0.91-6.64%
CLNNClene Inc.
$4.35+4.82%
COYACoya Therapeutics, Inc.
$4.89+2.73%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$152.71-1.36%
NVDANvidia
$222.27+1.34%
AGNCAGNC Investment Corp.
$9.87-0.40%
INTCIntel
$108.60-0.18%

Questions About OKYO

What is the current price of Okyo Pharma?

Okyo Pharma is trading at $1.36 per share.

What is the 52-week range for Okyo Pharma?

Over the past 52 weeks, Okyo Pharma has traded between $1.28 and $3.20.

How much debt does Okyo Pharma have?

As of the most recent reporting period, Okyo Pharma reported total debt of $0.00.

How much cash does Okyo Pharma have on hand?

Okyo Pharma reported $14.59M in cash and cash equivalents in its most recent financial results.

What is Okyo Pharma’s dividend yield?

Okyo Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services